A source of innovation

In 2010, LFB dedicated 38 million euros to biotechnological programs.
These new therapies are a major source of innovation and currently represent nearly half of all new drugs registered worldwide.

LFB, the leading French biotechnological company

According to the "Panorama of biotechnologies" in France edited by France Biotech, LFB is now the leading French biotechnology company.